Newsroom

  • AVEO Oncology Announces Completion of a CHMP Oral Explanation for Tivozanib as a Treatment of First-Line Renal Cell Carcinoma

    Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 19, 2017– AVEO Oncology (NASDAQ:AVEO) today announced its European licensee for tivozanib, EUSA Pharma, has completed an oral explanation to the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), as part of the Marketing Authorization Application (MAA) review process for tivozanib as a treatment for patients with

  • AVEO Announces Appointment of Matthew Dallas as Chief Financial Officer

    Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 16, 2017– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Matthew Dallas as chief financial officer, effective June 1, 2017. In this role, Mr. Dallas will be responsible for the Company’s financial strategy and management as it takes steps toward the potential commercialization of tivozanib. Mr. Dallas will also serve on the executive leadership team

  • AVEO Issues Statement Regarding the Passing of Lead Director Henri A. Termeer

    Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 15, 2017– The Board of Directors of AVEO Oncology (NASDAQ:AVEO) today issued the following statement regarding the passing of its Lead Director Henri A. Termeer. “We are deeply saddened at the loss of a visionary, mentor, colleague and dear friend, Henri A. Termeer. Henri’s wisdom, foresight and persistence fundamentally changed our industry, which exists

  • AVEO Oncology Announces Receipt of USPTO Notice of Allowance Related to AV-353

    Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 8, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/653,684, entitled “notch binding agents and antagonists and methods of use thereof.” Allowed under the application are composition of matter and method of use

  • AVEO Reports First Quarter 2017 Financial Results and Provides Business Update

    Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 4, 2017– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2017, and provided a business update. “We strengthened our balance sheet in the first quarter through an underwritten public offering, giving us the resources to potentially fund operations through the readout of our pivotal, Phase 3 TIVO-3 study

  • AVEO Announces Presentations at the 2017 ASCO Annual Meeting

    Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 20, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that poster presentations for three clinical studies will be presented at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2-6, 2017. Among these is a Trials in Progress presentation highlighting the ongoing Phase 3, randomized, controlled, multi-center, open-label TIVO-3 study comparing tivozanib, the Company’s potent, selective,

  • AVEO Announces Submission of Response to Tivozanib Marketing Authorization Application Day 180 List of Outstanding Issues

    Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 13, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that its European licensee for tivozanib, EUSA Pharma, has submitted responses to the European Medicines Agency (EMA) Day 180 List of Outstanding Issues (LOI) related to the Marketing Authorization Application (MAA) for tivozanib as a first-line treatment for renal cell carcinoma. With submission of the response complete,

  • AVEO Announces Milestone Payment from CANbridge for AV-203

    Download PDF Company Provides Updated Financial Guidance CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 3, 2017– AVEO Oncology (NASDAQ:AVEO) today announced receipt of a $500,000 milestone payment from CANbridge Life Sciences Ltd., a biopharmaceutical company focused on developing western drug candidates in China and North Asia, related to a technology transfer milestone for AV-203, AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate. AV-203 has demonstrated preclinical activity in

For media inquiries, please contact:

John F. Kouten, CEO
JFK Communications, Inc.
jfkouten@jfkhealth.com
Direct: 609-241-7352

The AVEO oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise with a proven track record for success in bringing important new therapies to patients.